Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We conducted a randomized trial of the treatment of multiple myeloma with high-dose chemotherapy followed by either one or two successive autologous stem-cell transplantations. METHODS: At the time of diagnosis, 399 previously untreated patients under the age of 60 years were randomly assigned to receive a single or double transplant. RESULTS: A complete or a very good partial response was achieved by 42 percent of patients in the single-transplant group and 50 percent of patients in the double-transplant group (P=0.10). The probability of surviving event-free for seven years after the diagnosis was 10 percent in the single-transplant group and 20 percent in the double-transplant group (P=0.03). The estimated overall seven-year survival rate was 21 percent in the single-transplant group and 42 percent in the double-transplant group (P=0.01). Among patients who did not have a very good partial response within three months after one transplantation, the probability of surviving seven years was 11 percent in the single-transplant group and 43 percent in the double-transplant group (P<0.001). Four factors were significantly related to survival: base-line serum levels of beta2-microglobulin (P<0.01) and lactate dehydrogenase (P<0.01), age (P<0.05), and treatment group (P<0.01). CONCLUSIONS: As compared with a single autologous stem-cell transplantation after high-dose chemotherapy, double transplantation improves overall survival among patients with myeloma, especially those who do not have a very good partial response after undergoing one transplantation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In earlier randomized trials, an improvement in OS was seen in two studies,132,133 but other studies failed to show such an improvement.134,135”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [132]
Citations
Cites
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Self-citationHigh-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768
BladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Moreau, P. (2002) · Blood · doi:10.1182/blood.v99.3.731 · Cited by 564
Fermand, J.-P., Ravaud, P., Chevret, S., Divine, M., Leblond, V., Belanger, C., Macro, M., Pertuiset, E., Dreyfus, F., Mariette, X., et al. (1998) · Blood · doi:10.1182/blood.v92.9.3131 · Cited by 542
Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma
Barlogie, B., Jagannath, S., Desikan, K. R., Mattox, S., Vesole, D., Siegel, D., Tricot, G., Munshi, N., Fassas, A., Singhal, S., et al. (1999) · Blood · doi:10.1182/blood.v93.1.55 · Cited by 472
(1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.12.3832 · Cited by 433
INTENSIVE TREATMENT OF MULTIPLE MYELOMA AND CRITERIA FOR COMPLETE REMISSION
Gore, M. E., Viner, C., Meldrum, M., Bell, J., Milan, S., Zuiable, A., Slevin, M., Selby, P. J., Clark, P. I., Millar, B., et al. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91548-1 · Cited by 190
Research works printed but not linked: 7
- Barlogie B, 1991, Bone Marrow Transplant, 7, 71
- Fermand J-P, 1999, Blood, 94, 396a
- Blade J, 2001, Blood, 98, 815a
- Palumbo A, 2001, Blood, 98, 849a
- Fermand J-P, 2001, Blood, 98, 815a
- Richardson P, 2002, Blood, 100, 104a
- Sirohi B, 2002, Bone Marrow Transplant, 29, S12
Cited by
Items 801–900 of 987
Autologous stem cell transplantation for multiple myeloma: history and future
Shimazaki, C. (2013) · Cited by 4
High-dose regimens for autologous stem cell transplantation
Fanning, S. R., & Sweetenham, J. W. (2009) · Elsevier eBooks · doi:10.1016/b978-0-443-10147-2.50030-8 · Cited by 1
Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma
Uchino, Y. (2015) · Journal of Nihon University Medical Association · doi:10.4264/numa.74.5_219 · Cited by 1
Lázár, E., Köpeczi, J. B., Kakucs, E., Benedek, I., Jakab, S., Pakucs, A., Tudor, C., & Benedek, I. (2017) · Journal of Interdisciplinary Medicine · doi:10.1515/jim-2017-0028 · Cited by 1
How I Manage Frontline Transplant-Eligible Multiple Myeloma in Italy
Montefusco, V., Martinelli, G., & Cerchione, C. (2020) · Hematology Reports · doi:10.4081/hr.2020.8954 · Cited by 1
Activity and outcomes of autologous stem cell transplantation in the private sector in Australia
Nath, K., James, Y., Taylor, D., Gardner, R., Rai, N., Ware, R. S., Taylor, K. M., Morton, J., Durrant, S., Irving, I., et al. (2022) · Internal Medicine Journal · doi:10.1111/imj.15754 · Cited by 1
Ladbury, C. J., Sanchez, J. F., Chowdhury, A., Palmer, J. M., Liu, A., Stein, A. S., Htut, M., Farol, L. T., Cai, J., Somlo, G., et al. (2024) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000001095 · Cited by 1
Fundamentals in the management of multiple myeloma.
Fadilah, S. A. W. (2010) · PubMed · Cited by 2
Setting the standard for newly diagnosed multiple myeloma
Laubach, J. P., Richardson, P. G. G., & Anderson, K. C. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.43 · Cited by 1
Pretransplant Induction Regimens for Multiple Myeloma
Vesole, D. H., & Siegel, D. S. D. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.12.013 · Cited by 1
Agarwal, R., & Abidi, M. H. (2012) · Hematology Reports · doi:10.4081/hr.2012.e26 · Cited by 1
Zaucha, R., Zaucha, J., Walewski, J. A., & Jassem, J. (2007) · Oncology in Clinical Practice · Cited by 1
Autologous stem cell transplantation for multiple myeloma
Nakamura, M., & Sunami, K. (2014) · Journal of Hematopoietic Cell Transplantation · doi:10.7889/hct.3.64 · Cited by 1
4. Role of Hematopoietic Stem Cell Transplantation in the Treatment of Lymphoid Malignancies.
Kanda, Y. (2011) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.100.1875 · Cited by 1
Multiple Myeloma and Other Plasma Cell Neoplasms
Mahindra, A. K., & Ng, A. K. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-24098-7.00078-2 · Cited by 2
Treatment of Transplant Eligible Patients with Multiple Myeloma
Sonneveld, P., Einsele, H., Brioli, A., & Cavo, M. (2017) · Hematologic malignancies · doi:10.1007/978-3-319-25586-6_3 · Cited by 2
Hematopoietic Cell Transplantation in Patients With Multiple Myeloma
Hussain, M. J., & Usmani, S. Z. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-56802-9.00017-1 · Cited by 1
VI. Standard Treatment for Multiple Myeloma
Ito, S., & Takano, M. (2016) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.105.1238 · Cited by 1
Romano, A., Santoro, M., Conticello, C., Siragusa, S. M., Raimondo, F. D., Martinelli, G., & Cerchione, C. (2021) · Panminerva Medica · doi:10.23736/s0031-0808.20.04141-5 · Cited by 1
TREATMENT OF NEWLY DIAGNOSED MULTIPLE MYELOMA
Rajkumar, S. V., & Kyle, R. A. (2008) · Cambridge University Press eBooks · doi:10.1017/cbo9780511551901.003 · Cited by 1
Naithani, R., Dayal, N., & Rai, R. (2020) · South Asian Journal of Cancer · doi:10.1055/s-0041-1727068 · Cited by 1
Kostroma, I. I., Sidorova, Z. Y., Semenova, N. Y., Zherniakova, A., Sabitova, R., Свитина, С. П., Stepchenkova, E. I., Бессмельцев, С. С., Чечеткин, А. В., & Грицаев, С. В. (2021) · Clinical oncohematology · doi:10.21320/2500-2139-2021-14-3-333-339 · Cited by 2
The Molecular Biology of Multiple Myeloma
Chng, W. J., & Bergsagel, P. L. (2010) · Wiley eBooks · doi:10.1002/9781444318531.ch11 · Cited by 1
High‐dose Preparatory Regimens
Bensinger, W. (2015) · Wiley eBooks · doi:10.1002/9781118416426.ch20 · Cited by 1
Krishnan, A. Y., Nathwani, N., Amanam, I. U., & Gupta, R. (2019) · Springer eBooks · doi:10.1007/978-3-030-31471-2_5 · Cited by 1
Semochkin, S. V. (2025) · Clinical oncohematology · doi:10.21320/2500-2139-2020-13-1-1-24 · Cited by 3
Is double autologous stem-cell transplantation appropriate for new multiple myeloma patients?
van Rhee, F. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1005 · Cited by 1
Exciting new agents in multiple myeloma
Merlini, G. (2006) · Blood · doi:10.1182/blood-2006-09-042978 · Cited by 1
Role of autologous stem cell transplantation in multiple myeloma
Kumar, S. K. (2007) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-007-0017-z · Cited by 1
“The IFM-94 trial randomized previously untreated patients to a single or double transplant [ 36 ].”
Eom, K., Min, C., Lee, S., Kim, Y., Kim, S., Cho, S., Lee, J., Min, W.-S., & Kim, C.-C. (2006) · The Korean Journal of Hematology · doi:10.5045/kjh.2006.41.1.36 · Cited by 1
Transplantation for Myeloma: Work in Progress
Palumbo, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.1437 · Cited by 2
Maximizing the clinical benefit of novel therapies in multiple myeloma.
Laubach, J. P., Mitsiades, C. S., Anderson, K. C., & Richardson, P. G. G. (2009) · PubMed · Cited by 1
4.15 Knochenmark- und Blutstammzelltransplantation
(1999) · Thieme eBooks · doi:10.1055/b-0034-12166 · Cited by 1
Novel Agents for Previously Untreated Multiple Myeloma
Thomas, S. K., Richards, T. A., & Weber, D. M. (2007) · Translational medicine series · doi:10.3109/9781420045116.008 · Cited by 1
Kyle, R. A., & Dispenzieri, A. A. (2008) · Elsevier eBooks · doi:10.1016/b978-0-323-04404-2.10078-8 · Cited by 1
Wang, J., Zhang, Q., Zhou, R., Chen, B., & Ouyang, J. (2012) · PLoS ONE · doi:10.1371/annotation/928a7cff-1ae7-4ce5-908c-f765ea53663f · Cited by 1
High-Dose Therapy in Multiple Myeloma
Harousseau, J. (2007) · Translational medicine series · doi:10.3109/9781420045116.010 · Cited by 1
Self-citationThalidomide: Induction Therapy
Buadi, F. K., & Rajkumar, S. V. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-564-0_14 · Cited by 1
The Use of Bortezomib in Autologous Transplantation for Multiple Myeloma
Langston, A. A., & Lonial, S. (2010) · Springer eBooks · doi:10.1007/978-3-7643-8948-2_5
“Improvements in overall survival for patients with multiple myeloma were first achieved in the mid 1990s with widespread use of high dose therapy (HDT) and autologous transplantation [1, 2 ]. During this period, it became clear that HDT was able to overcome drug resistance, leading to clinical benefit even in the cont…”
BackgroundEinsele, H., Knop, S. T., & Straka, C. (2010) · Der Onkologe · doi:10.1007/s00761-010-1791-0 · Cited by 1
Tricot, G. J. K., Zangari, M., Sorasio, R., & Bruno, B. (2008) · Cancer treatment and research · doi:10.1007/978-0-387-78580-6_14
Immunological and Clinical Long-Term Effects of Idiotype Vaccination in Multiple Myeloma Patients
Abdalla, A. O. (2007) · Figshare
Multiple Myeloma: Molecular Biology, Diagnosis and Treatment
Kumar, S. K., & Rajkumar, S. V. (2011) · Wiley eBooks · doi:10.1002/9781444394016.ch20
Clinical and biological aspects of Multiple Myeloma
Hovenga, S. (2007) · University of Groningen research database (University of Groningen / Centre for Information Technology)
Stem Cell Mobılızatıon in Multıple Myeloma
Mine, U., & Demirer, T. (2012) · InTech eBooks · doi:10.5772/30794
Rodríguez, F. D. L., & José, C. (2011) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)
Fleissner, C., Heider, U., Jakob, C., Zavrski, I., & Sezer, O. (2007) · Elsevier eBooks · doi:10.1016/b978-343723770-6.50018-1
Population-based studies on familiality and prognosis in patients with monoclonal gammopathies
Kristinsson, S. Y. (2009) · Figshare · Cited by 1
Alternative Sources of Hematopoietic Stem Cells and Their Clinical Applications
Gutman, J. A., Heimfeld, S., & Deeg, H. J. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3764-2_57
Treatment of transplant-eligible patients
Mohty, M., Malard, F., & Harousseau, J. (2015) · Springer eBooks · doi:10.1007/978-3-319-18218-6_3
Self-citationAutologous Stem Cell Transplantation in the Management of Multiple Myeloma
Gertz, M. A., & Reeder, C. B. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8520-9_10
Konventionelle Therapieverfahren
Glaß, B., Hünerbein, M., Pfeifer, B., Preiß, J., Schlag, P. M., Schürmann, M., Seegenschmiedt, M. H., Sinzinger, H. F., Trümper, L. H. P., Unger, C., et al. (2006) · Elsevier eBooks · doi:10.1016/b978-343756420-8.50015-9
Breuer, K., Cornely, O. A., Dreyling, M. H., Goldschmidt, H., Hallek, M. J., Hartmann, F., Korfel, A., Link, H., Matzdorff, A. C., & THIEL, E. (2006) · Elsevier eBooks · doi:10.1016/b978-343756420-8.50030-5
Ladická, M., Ballová, V., Drgoňa, Ľ., Vranovský, A., & Lakota, J. (2012) · Neoplasma · doi:10.4149/neo_2012_071
“CD 34+ selection in 1st transplantation 2nd transplantation 9 (10) 3 (3.”
BackgroundResultInfluentialGranulocyte and erythropoietic stimulating proteins after high-dose chemotherapy for myeloma
Littlewood, T. J., & Collins, G. P. (2007) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705845
Treatment of elderly patients with hematological diseases
Imamura, M. (2007) · Nippon Ronen Igakkai Zasshi Japanese Journal of Geriatrics · doi:10.3143/geriatrics.44.587
Allogeneic transplantation in multiple myeloma
Majolino, I., & Severino, A. (2009) · Revista Brasileira de Hematologia e Hemoterapia · doi:10.1590/s1516-84842009000800011
Timing of Stem Cell Transplantation in the Era of Novel Agents
Weber, D. M. (2009) · Clinical Lymphoma & Myeloma · doi:10.1016/s1557-9190(11)70832-0
Phase III Studies Published by the IFM (Intergroupe Francophone du Myélome)
Moreau, P. (2009) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2009.s.005
Transplante de células-tronco hematopoéticas em gamopatias monoclonais
Maiolino, Â., Solza, C., Barros, J. C., Coelho, É., Magalhães, R., Bittencourt, R., Atalla, Â., Carnevalli, E., Roithmann, S., & Hungria, V. (2010) · Revista Brasileira de Hematologia e Hemoterapia · doi:10.1590/s1516-84842010005000017
O transplante autólogo de células-tronco hematopoéticas no tratamento do Mieloma Múltiplo
Maiolino, Â., & Magalhães, R. (2007) · Revista Brasileira de Hematologia e Hemoterapia · doi:10.1590/s1516-84842007000100009
Is there a role for 'modified VAD' in the treatment of multiple myeloma?
Agazzi, A. (2010) · ecancermedicalscience · doi:10.3332/ecancer.2009.136
“Novel thalidomide-based combination therapies (Thal/Dex [19], Thal/MP [20], Thal/Dex/PegLD [21], Lenalidomide-based: Lenalidomide/Dex [22], Claritromycin/ Lenalidomide/Dex [23], Lenalidomide/MP [24] and bortezomibbased: Bortezomib/Dex [25], Bortezomib/DT-Pace [26], Bortezomib/Adria/Dex [27], Bortezomib/Thal/Dex [28],…”
Lissandre, S., Schmidt, A., Moles, M., & Ifrah, N. (2007) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(07)80396-0
Qazilbash, M. H., & Giralt, S. (2009) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2009.s.007
Martino, M. V., Callea, I., Moscato, T., Pontari, A., Spiniello, E., & Fedele, R. (2012) · Open Journal of Blood Diseases · doi:10.4236/ojbd.2012.23012
“sponse rate, event free, and overall survival [17-20].”
BackgroundTHE BELGIAN 2010 CONSENSUS RECOMMENDATIONS FOR THE TREATMENT OF MULTIPLE MYELOMA
Schots, R., Delforge, M., André, M. P. E., Bries, G., Caers, J., Demuynck, H., Prijck, B. D., Samblanx, H. D., Kentos, A., Meuleman, N., et al. (2010) · Acta Clinica Belgica · doi:10.1179/acb.2010.055
“The addition of a second highdose melphalan + ASCT improves survival furthermore, but this advantage is signifi cant only for pts not achieving CR/VGPR after the fi rst transplantation (37).”
BackgroundSelf-citationTan, Y., Xu, S., Li, X., & Chen, J. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010484.pub2
I04 Stem cell transplantation in multiple myeloma
Gahrton, G. (2007) · Blood Reviews · doi:10.1016/s0268-960x(07)70005-x
Efficacy of repeat myeloablative chemotherapy with autologous stem-cell support in multiple myeloma
Menzel, H., Hinmüller, K., Kolb, H., Schuster, T., Höllein, A., Peschel, C., Dechow, T. N., & Keller, U. B. (2012) · Therapeutic Advances in Hematology · doi:10.1177/2040620711433317
“Based on our results and the existing literature we recommend considering relapse treatment with new agents and late HD-Mel/autoSCT for selected patients, potentially as bridge to alloSCT.”
ResultInfluentialMahtouk, K., Vos, J. D., Moreaux, J., Jourdan, M., Baudard, M., Rossi, J. F., Reme, T. X., & Klein, B. (2007) · Hématologie · doi:10.1684/hma.2007.0141
“Le MM est une pathologie toujours incurable en 2006, avec une moyenne de survie de 5 ans après chimiothérapie intensive et greffe de cellules souches hématopoïétiques autologues [5].”
Background[Hematopoietic stem cell transplantation in autoimmune diseases].
Albarracín, F., Meiller, M. J. L., Nasswetter, G. G., & Longoni, H. (2008) · PubMed
Therapiekonzepte bei jüngeren Patienten mit multiplem Myelom
Einsele, H., Knop, S. T., & Straka, C. (2014) · Der Onkologe · doi:10.1007/s00761-013-2570-5
Is tandem autotransplantation necessary in myeloma?
Jagannath, S. (2008) · Blood · doi:10.1182/blood-2007-10-115287
Overview of the Lymphoid Neoplasms
Podoltsev, N. A., Lacy, J., & Vose, J. M. (2010) · Springer eBooks · doi:10.1007/978-1-4419-7668-0_1
Multiple Myeloma in a 50-Year-Old with an HLA-Identical Sibling
Koreth, J. (2007) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2007.08.042
Single Versus Tandem Autologous Hematopoietic Stem Cell Transplant in Multiple Myeloma
Vesole, D. H. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-478-0_10
“In the IFM 94 trial, the probability of 7-year survival was 11% with single transplant versus 43% with the tandem approach [ 24 ].”
MethodInfluentialImproved Survival in Patients with Multiple Myeloma Treated with DMVM plus IFN-.ALPHA.
Kitani, T., Tokumine, Y., Masaoka, T., Horiuchi, A., Kakishita, E., Kageyama, T., Tatsumi, N., Kuyama, J., Hayashi, K., Tsukaguchi, M., et al. (2005) · Journal of the Japan Society of the Reticuloendothelial System · doi:10.3960/jslrt.45.71
Kurita, N., Nagasawa, T., & Komatsu, T. (2005) · Journal of the Japan Society of the Reticuloendothelial System · doi:10.3960/jslrt.45.93
Czekalla, H. (2010) · Multimedialen Archiv und Publikationsserver der Christian-Albrechts-Universität zu Kiel (Christian-Albrechts-Universität zu Kiel)
Autologe Stammzelltransplantation bei Myelompatienten: Ansätze zur Verbesserung der Ergebnisse
Zojer, N. (2015) · Wiener klinisches Magazin · doi:10.1007/s00740-015-0077-y
Strategies for reducing damage while optimizing therapeutic dosage
Wiebe, E. M., & Rodrigues, G. (2006)
Allogeneic Transplantation for the Treatment of Multiple Myeloma
Olin, R. L., Vogl, D. T., & Stadtmauer, E. A. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-478-0_16
“The IFM94 randomized trial demonstrated an improved median OS with tandem autologous transplants when compared to a single transplant [15]; 7- year survival was 43% in the group randomized to tandem transplants vs.”
MethodConcise of the Disease and Treatment Options
Durie, B. G. M. (2015)
Murakami, H., Shimizu, K., & Takagi, T. (2015)
Darskaya, Y. I., Марами-Зонузи, Н. Э., & Osipov, Y. S. (2014) · DOAJ (DOAJ: Directory of Open Access Journals) · doi:10.17650/1818-8346-2014-9-1-6-10
Niesvizky, R., Durie, B. G. M., Lonial, S., Kröger, N. M., Gahrton, G., Bergsagel, P. L., Vesole, D. H., Einsele, H., Anderson, K. C., Richardson, P. G. G., et al. (2012)
Self-citationTraitement du myélome multiple
Casassus, P. (2013) · Encyclopédie médico-chirurgicale. Hématologie · doi:10.1016/s1155-1984(12)50916-7
Szpiczak plazmocytowy — praktyczne aspekty dotyczące diagnostyki i leczenia
Charliński, G., & Wiater, E. (2014) · Cited by 1
Rajkumar, S. V., Sonneveld, P., Sezer, O., Vesole, D. H., Cavo, M., Einsele, H., Richardson, P. G. G., Ludwig, H., Bergsagel, P. L., Bladé, J., et al. (2009)
Self-citationDiagnosis and treatment of multiple myeloma. Recent advance
Okamoto, S. (2006) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.95.1922
Бессмельцев, С. С. (2013) · Clinical oncohematology · doi:10.21320/2500-2139-2013-6-4-379-414 · Cited by 7
Gallop‐Evans, E., & Poynton, C. (2008) · Cambridge University Press eBooks · doi:10.1017/cbo9780511545375.032
Therapeutic decision making in hematopoietic SCT for multiple myeloma
Munker, R., Lazarus, H. M., & Atkinson, K. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139519205.012
Therapeutic decision making in hematopoietic stem cell transplantation for multiple myeloma
Ballester, O. (2009) · Cambridge University Press eBooks · doi:10.1017/cbo9780511575525.011
Bone Marrow and Peripheral Blood Stem Cell Transplantation
Benn, H., & Rowley, S. D. (2007) · Elsevier eBooks · doi:10.1016/b978-0-443-06981-9.50063-6 · Cited by 3
Multiple myeloma: management of de novo disease to include HDT
Guglielmelli, T., Sonneveld, P., Broyl, A., & Palumbo, A. P. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9780511862465.011
R, R. S., J, S. M., Nair, B., & Jayakumar, K. L. (2017) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20170828
Stem Cell Transplantation for Multiple Myeloma
Thanendrarajan, S., & Garg, T. K. (2017) · Stem cell biology and regenerative medicine · doi:10.1007/978-3-319-51833-6_5
Metadata
- Authors
- Attal, M., Harousseau, J.-L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.-G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., Voillat, L., Sotto, J.-J., Grosbois, B., & Bataille, R.
- Affiliations
- Hôpital Purpan (FR)
- Hôpital Claude Huriez (FR)
- Centre Hospitalier Universitaire de Poitiers (FR)
- Centre Hospitalier Universitaire de Nice (FR)
- Centre Henri Becquerel (FR)
- Centre Hospitalier Régional et Universitaire de Nancy (FR)
- CHU Dijon Bourgogne (FR)
- Centre Hospitalier Universitaire de Besançon (FR)
- Hôpital Albert Michallon (FR)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-12-25
- Volume
- 349
- Issue
- 26
- Pages
- 2495-2502
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1982499121
- Cited by
- 984
- References
- 16
- Citations by year
- 2026: 3 · 2025: 13 · 2024: 18 · 2023: 14 · 2022: 22 · 2021: 20 · 2020: 33 · 2019: 18 · 2018: 35 · 2017: 28 · 2016: 24 · 2015: 37 · 2014: 38 · 2013: 53 · 2012: 42
- FWCI
- 34.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Libraries (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Keywords
- multiple myeloma, autologous stem cell transplantation, high-dose chemotherapy, overall survival, event-free survival, very good partial response, beta2-microglobulin, lactate dehydrogenase, prognostic factors
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Combined Modality Therapy, Dexamethasone, Doxorubicin, Female, Humans, Male, Middle Aged, Multiple Myeloma, Neoplasm Staging, Prognosis, Transplantation, Autologous, Vincristine, Survival Rate, Multivariate Analysis, Hematopoietic Stem Cell Transplantation, Disease-Free Survival, Transplantation Conditioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.